SAT-676 - Indirect treatment comparison Oral Orforglipron vs. Oral Semaglutide 25 mg

Co-Author(s)

• DJ

  David Jacobi, n/a

  Nantes Université, CHU Nantes, CNRS, Inserm, L’institut du Thorax
  Nantes, France
• SV

  Simona Vasileva-Metodiev, MSc

  Eli Lilly and Company
  Indianapolis, Indiana, United States
• KV

  Karan Vadher, n/a

  Eli Lilly and Company
  Indianapolis, IN, United States
• TP

  Tommaso Panni, n/a

  Eli Lilly and Company
  Indianapolis, IN, United States
• SZ

  Sarah Zimner-Rapuch, n/a

  Eli Lilly and Company
  Indianapolis, IN, United States

Late-Breaking Poster Presenter(s)

• SS

  Shraddha Shinde, BPharm, MS, MBA

  Senior Research Scientist
  Eli Lilly and Company
  Indianapolis, Indiana, United States

Co-Author(s)

• MR

  Manon Rubinstein, n/a

  Costello Medical
  London, United Kingdom
• LC

  Laura J. Clark, n/a

  Costello Medical
  Manchester, United Kingdom
• MP

  Maarten J. Postma, n/a

  University Medical Center Groningen
  Groningen, Netherlands